Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5657668 | Clinical Gastroenterology and Hepatology | 2017 | 15 Pages |
Abstract
Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed an observational study to determine the incidence of and factors associated with hepatitis in 327 patients receiving pan-oral DAA agents for HCV infections in areas endemic for HBV in China. Ten patients were positive for hepatitis B surface antigen (HBsAg), and 124 patients had occult HBV infection. HBV reactivation was determined by measuring HBV DNA and HBsAg status in serial serum samples collected every 2 weeks during DAA treatment and then every 4 weeks after treatment until week 12. In the total study population, 10 patients (3.1%) had hepatitis; 3 cases were associated with HBV reactivation (1 case not in the icteric phase, 1 case in the icteric phase, and 1 case with liver failure) and 7 from other causes. Testing positive for HBsAg before DAA treatment was a strong risk factor for developing hepatitis during treatment (hazard ratio, 15.0; P < .001).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Cheng Wang, Dong Ji, Jing Chen, Qing Shao, Bing Li, Jialiang Liu, Vanessa Wu, April Wong, Yudong Wang, Xiaoyong Zhang, Lei Lu, Chris Wong, Stella Tsang, Zheng Zhang, Jian Sun, Jinlin Hou, Guofeng Chen, George Lau,